Skip to main content
. 2021 Aug 17;33(1):273–282. doi: 10.1007/s00198-021-06067-2

Fig. 2.

Fig. 2

Comparison of COVID-19 outcomes among the three anti-osteoporosis drug users and relative risks of outcomes compared to control group (ICU, intensive care unit)